BR0009333A - Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterol - Google Patents
Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterolInfo
- Publication number
- BR0009333A BR0009333A BR0009333-5A BR0009333A BR0009333A BR 0009333 A BR0009333 A BR 0009333A BR 0009333 A BR0009333 A BR 0009333A BR 0009333 A BR0009333 A BR 0009333A
- Authority
- BR
- Brazil
- Prior art keywords
- cholesterol
- lipg
- apolipoprotein
- level
- increase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"COMPOSIçãO PARA REDUZIR A EXPRESSãO DO GENE LIPG E A ATIVIDADE ENZIMáTICA DO POLIPEPTìDEO DE LIPG, PARA INIBIR A ATIVIDADE ENZIMáTICA DO POLIPEPTìDEO DE LIPG., PARA AUMENTAR O NìVEL E A ATIVIDADE ENZIMáTICA DE POLIPEPTìDEO LIPG EM UM PACIENTE E MéTODOS PARA AUMENTAR O NìVEL DE COLESTEROL DE LIPOPROTEìNA DE ALTA DENSIDADE E APOLIPOPROTEìNA AI, PARA REDUZIR O NìVEL DE COLESTEROL DE LIPOPROTEìNA DE DENSIDADE MUITO BAIXA E DE COLESTEROL LDL E COLESTEROL VLDL EM UM PACIENTE, PARA DIAGNOSTICAR UMA PREDISPOSIçãO PARA BAIXOS NìVEIS DE COLESTEROL HDL E A APOLIPOPROTEìNA AI, E PARA DETERMINAR SE UM COMPOSTO DE TESTE PODE INIBIR A REAçãO ENZIMáTICA ENTRE O POLIPEPTìDEO DE LIPG E O COLESTEROL HDL E APOLIPOPROTEìNA AI E PODE AUMENTAR A REAçãO ENZIMáTICA ENTRE O POLIPEPTìDEO DE LIPG E O COLESTEROL VLDL E VDL". Composições e métodos para elevar o nível de colesterol HDL e apolipoproteína AI em um paciente e reduzir os níveis de colesterol VLDL e colesterol LDL em um paciente, que inclui composições e métodos que efetuam a expressão de um gene, LIPG, que codifica uma enzima lipase, que é um membro da família de triacilglicerol lipase ou que efetua a atividade enzimática da enzima."COMPOSITION TO REDUCE THE EXPRESSION OF THE LIPG GENE AND THE ENZYMATIC ACTIVITY OF THE LIPG POLYPEPTIDE, TO INHIBIT THE ENZYMATIC ACTIVITY OF THE LIPG POLYPEPTIDE. HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN AI, TO REDUCE THE VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL AND LDL CHOLESTEROL AND VLDL CHOLESTEROL IN A PATIENT, TO DIAGNOSTIC A HIGH-LOW PROSPECTIVE COLLECTIONS DETERMINING IF A TEST COMPOUND CAN INHIBIT THE ENZYMATIC REACTION BETWEEN LIPG POLYPEPTIDE AND CHOLESTEROL HDL AND APOLIPOPROTEIN AI AND MAY INCREASE THE ENZYMATIC REACTION BETWEEN LIPG AND COLES POLYPEPTIDE. Compositions and methods for raising the level of HDL cholesterol and AI apolipoprotein in a patient and reducing the levels of VLDL cholesterol and LDL cholesterol in a patient, which includes compositions and methods that effect the expression of a gene, LIPG, which encodes a lipase enzyme , which is a member of the triacylglycerol lipase family or which carries out the enzymatic activity of the enzyme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
| PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0009333A true BR0009333A (en) | 2002-01-08 |
Family
ID=23060703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0009333-5A BR0009333A (en) | 1999-03-26 | 2000-03-24 | Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterol |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1171078A4 (en) |
| JP (1) | JP2002540127A (en) |
| KR (2) | KR20050044812A (en) |
| AU (1) | AU776684B2 (en) |
| BR (1) | BR0009333A (en) |
| CA (1) | CA2363486C (en) |
| HK (1) | HK1043309A1 (en) |
| IL (2) | IL145526A0 (en) |
| MX (1) | MXPA01009727A (en) |
| NO (2) | NO331779B1 (en) |
| NZ (2) | NZ514350A (en) |
| WO (1) | WO2000057837A2 (en) |
| ZA (1) | ZA200107598B (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
| EP2370581B1 (en) | 2008-12-04 | 2016-08-03 | CuRNA, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| RU2618688C2 (en) | 2008-12-04 | 2017-05-10 | КьюРНА,Инк.,US | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
| CA2745329C (en) | 2008-12-04 | 2022-07-12 | Opko Curna, Llc | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
| EP2396038B1 (en) | 2009-02-12 | 2015-10-21 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
| CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| EP2427553A4 (en) | 2009-05-06 | 2012-11-07 | Opko Curna Llc | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| JP5931720B2 (en) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Treatment of dystrophin family-related diseases by suppression of natural antisense transcripts on the DMD family |
| JP5922017B2 (en) | 2009-05-18 | 2016-05-24 | クルナ・インコーポレーテッド | Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor |
| US8895527B2 (en) | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
| US8791085B2 (en) | 2009-05-28 | 2014-07-29 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| CA2765509C (en) | 2009-06-16 | 2021-08-17 | Joseph Collard | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
| CN102695797B (en) | 2009-06-16 | 2018-05-25 | 库尔纳公司 | By inhibiting to treat the relevant disease of glue protogene for the natural antisense transcript of glue protogene |
| CN102597238B (en) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2) |
| EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| JP2013500017A (en) | 2009-07-24 | 2013-01-07 | カッパーアールエヌエー，インコーポレイテッド | Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT) |
| KR101802536B1 (en) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
| KR101827015B1 (en) | 2009-08-11 | 2018-02-07 | 큐알엔에이, 인크. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| EP2467482A4 (en) | 2009-08-21 | 2013-12-11 | Curna Inc | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| US9023822B2 (en) | 2009-08-25 | 2015-05-05 | Curna, Inc. | Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP |
| CN102791861B (en) | 2009-09-25 | 2018-08-07 | 库尔纳公司 | FLG relevant diseases are treated by adjusting expression and the activity of Filaggrin (FLG) |
| CA2782366A1 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
| EP2516648B1 (en) | 2009-12-23 | 2017-11-08 | CuRNA, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
| US8962585B2 (en) | 2009-12-29 | 2015-02-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
| RU2615450C2 (en) | 2009-12-29 | 2017-04-04 | Курна, Инк. | Treating diseases associated with nuclear respiratory factor 1 (nrf1) by inhibition of natural antisense transcript to nrf1 |
| WO2011082281A2 (en) | 2009-12-31 | 2011-07-07 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| JP5886757B2 (en) | 2010-01-04 | 2016-03-16 | カッパーアールエヌエー，インコーポレイテッド | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcripts against interferon regulatory factor 8 (IRF8) |
| EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
| CA2786535C (en) | 2010-01-11 | 2019-03-26 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
| JP5976548B2 (en) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー，インコーポレイテッド | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1 |
| US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
| US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
| EP2957636B1 (en) | 2010-05-03 | 2020-04-01 | CuRNA, Inc. | Treatment of sirtuin 3 (sirt3) related diseases by inhibition of natural antisense transcript to sirt3 |
| TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of PAR4-related diseases by inhibiting PAR4 natural anti-strand transcript |
| WO2011150005A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| CA2799596C (en) | 2010-05-26 | 2020-09-22 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| DK2585596T3 (en) | 2010-06-23 | 2021-04-06 | Curna Inc | TREATMENT OF VOLTAGE REGULATED SODIUM CHANNEL ALPHA SUBSIDY (SCNA) -RELATED DISEASES IN INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA |
| NO2593547T3 (en) | 2010-07-14 | 2018-04-14 | ||
| EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
| KR101865433B1 (en) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| WO2012170771A1 (en) | 2011-06-09 | 2012-12-13 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
| CN103874486A (en) | 2011-09-06 | 2014-06-18 | 库尔纳公司 | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
| JP2015511494A (en) | 2012-03-15 | 2015-04-20 | キュアナ，インク． | Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF) |
| CN102628060A (en) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | Production method of low-fat milk |
| JP6362268B2 (en) | 2012-11-05 | 2018-07-25 | 塩野義製薬株式会社 | Method for evaluating drug efficacy and screening method for EL activity inhibitory substance having therapeutic or preventive effect on diseases associated with EL activity |
| KR102034478B1 (en) * | 2013-03-14 | 2019-10-21 | 시오노기 앤드 컴파니, 리미티드 | Monoclonal antibody inhibiting enzymatic activity of endothelial lipase |
| TWI688575B (en) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
| CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| JPWO2023008337A1 (en) * | 2021-07-26 | 2023-02-02 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0707638A4 (en) * | 1992-12-04 | 1998-05-20 | Innovir Lab Inc | REGULABLE NUCLEIC ACID FOR THERAPEUTIC USE AND METHODS OF USE THEREOF |
| CA2273823C (en) * | 1996-12-06 | 2007-06-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
| WO1999032611A1 (en) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20100214L (en) | 2001-11-21 |
| CA2363486A1 (en) | 2000-10-05 |
| KR20050044812A (en) | 2005-05-12 |
| MXPA01009727A (en) | 2002-07-22 |
| EP1171078A2 (en) | 2002-01-16 |
| NO20014657D0 (en) | 2001-09-25 |
| AU3918700A (en) | 2000-10-16 |
| WO2000057837A2 (en) | 2000-10-05 |
| WO2000057837A3 (en) | 2001-01-25 |
| NZ514350A (en) | 2004-12-24 |
| JP2002540127A (en) | 2002-11-26 |
| WO2000057837A8 (en) | 2001-09-27 |
| NZ531180A (en) | 2005-06-24 |
| EP1171078A4 (en) | 2002-11-06 |
| HK1043309A1 (en) | 2002-09-13 |
| ZA200107598B (en) | 2003-05-28 |
| IL145526A (en) | 2010-11-30 |
| IL145526A0 (en) | 2002-06-30 |
| NO331784B1 (en) | 2012-03-26 |
| KR20020029651A (en) | 2002-04-19 |
| AU776684B2 (en) | 2004-09-16 |
| CA2363486C (en) | 2012-12-18 |
| NO331779B1 (en) | 2012-03-26 |
| WO2000057837A9 (en) | 2001-10-18 |
| NO20014657L (en) | 2001-11-21 |
| KR100887164B1 (en) | 2009-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0009333A (en) | Composition to reduce lipg gene expulsion and the enzymatic activity of the lipg polypeptide, to inhibit the enzymatic activity of the lipg polypeptide, to increase the level and enzymatic activity of the lipg polypeptide in a patient and methods to increase the cholesterol level of high density lipoprotein and apolipoprotein ai, to reduce the level of very low density lipoprotein cholesterol and ldl cholesterol and vldl cholesterol in a patient, to diagnose a predisposition to low levels of hdl cholesterol and apolipoprotein ai, and to determine whether a test compound can inhibit the enzymatic reaction between lipg polypeptide and hdl cholesterol and apolipoprotein ai and can increase the enzymatic reaction between lipg polypeptide and vldl and vdl cholesterol | |
| Li-Saw-Hee et al. | Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.: Relationship to left ventricular mass and anti-hypertensive therapy | |
| Hattori et al. | Purification and characterization of bovine brain platelet-activating factor acetylhydrolase. | |
| Drake et al. | Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned | |
| Gur et al. | Paraoxonase and arylesterase activities in coronary artery disease | |
| Mackness et al. | Human serum paraoxonase | |
| Dean et al. | Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. | |
| MACKNESS et al. | Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy | |
| Nishimoto et al. | Increased local angiotensin II formation in aneurysmal aorta | |
| CN100410388C (en) | A method for identifying compounds that increase bone mineral density | |
| US6613322B2 (en) | Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase | |
| Sutherland et al. | Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women | |
| Maisi et al. | Soluble membrane‐type 1 matrix metalloproteinase (MT1‐MMP) and gelatinase A (MMP‐2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis | |
| Giguère et al. | The association between heel ultrasound and hormone replacement therapy is modulated by a two‐locus vitamin D and estrogen receptor genotype | |
| Takahashi et al. | Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone | |
| Sultan et al. | Calpain activity in fast, slow, transforming, and regenerating skeletal muscles of rat | |
| Mercier et al. | Semicarbazide‐Sensitive Amine Oxidase Increases in Calcific Aortic Valve Stenosis and Contributes to Valvular Interstitial Cell Calcification | |
| Rosenblat et al. | VLDL triglycerides inhibit HDL‐associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies | |
| Yoshino et al. | Atherogenic lipoproteins and diabetes mellitus | |
| Munroe et al. | Tissue-specific expression of human arylsulfatase-C isozymes and steroid sulfatase | |
| Hartley et al. | Osteoarthritis: insights offered by the study of bone mass genetics | |
| Ebara et al. | No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61→ stop) in the lipoprotein lipase gene | |
| Feng et al. | Inhibition of the mitogen activated protein kinase, p38α, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading | |
| Krause et al. | Section Review—Cardiovascular & Renal: Emerging Therapies in Atherosclerosis | |
| Zha et al. | Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O 11, 13, 25 DA LPI |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |